Beth C. Seidenberg - 18 Dec 2025 Form 4 Insider Report for Kyverna Therapeutics, Inc. (KYTX)

Role
Director
Signature
By: /s/ Jennifer L. Kercher, as Attorney-in-Fact
Issuer symbol
KYTX
Transactions as of
18 Dec 2025
Net transactions value
+$999,998
Form type
4
Filing time
22 Dec 2025, 11:43:43 UTC
Previous filing
10 Jun 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
SEIDENBERG BETH C Director C/O KYVERNA THERAPEUTICS, INC., 5980 HORTON ST., STE 550, EMERYVILLE By: /s/ Jennifer L. Kercher, as Attorney-in-Fact 22 Dec 2025 0001184592

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction KYTX Common Stock Purchase $999,998 +133,333 +18% $7.50 869,317 18 Dec 2025 See Footnote F1
holding KYTX Common Stock 3,787,940 18 Dec 2025 See Footnote F2
holding KYTX Common Stock 16,634 18 Dec 2025 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Shares held directly by Westlake BioPartners Opportunity Fund I, L.P. ("Westlake Opportunity"). The general partner of Westlake Opportunity is Westlake BioPartners Opportunity GP I, LLC ("Westlake Opportunity GP I"). The Reporting Person is the managing director of Westlake Opportunity GP I and has sole voting and dispositive control over Westlake Opportunity GP I, and disclaims beneficial ownership of the shares held by Westlake Opportunity except to the extent of the Reporting Person's pecuniary interest therein, if any.
F2 Shares held directly by Westlake BioPartners Fund I, L.P. ("Westlake I"). The general partner of Westlake I is Westlake BioPartners GP I, LLC ("Westlake GP I"). The Reporting Person is the managing director of Westlake GP I and has sole voting and dispositive control over Westlake GP I, and disclaims beneficial ownership of the shares held by Westlake I except to the extent of the Reporting Person's pecuniary interest therein, if any.
F3 Represents a restricted stock unit award of common stock, which will vest in full on the earlier of (i) May 29, 2026, and (ii) immediately prior to the date of the Issuer's 2026 annual meeting of stockholders, subject to the Reporting Person's continuous service to the Issuer on and through each applicable vesting date, inclusive.